A carregar...

The Use of Chimeric Antigen Receptor T Cells in Patients With Non-Hodgkin Lymphoma

Resistance to conventional lines of therapy develops in approximately 20% of all patients with lymphoma. These patients have a dismal prognosis, with an expected median survival of 6.3 months. In recent years, T-cell immunotherapy has demonstrated a remarkable capacity to induce complete and durable...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Adv Hematol Oncol
Main Authors: Lulla, Premal D., Hill, LaQuisa C., Ramos, Carlos A., Heslop, Helen E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469642/
https://ncbi.nlm.nih.gov/pubmed/29851933
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!